The medical devices sector is typified by frequent change and innovation, in response to problems and issues faced by the healthcare industry. As a result, the sector has seen the emergence of several start-up medtech companies offering disruptive, cutting-edge solutions. Most of these are private companies, where data such as revenue is frequently not disclosed. National estimates for RareCyte sales in the US from 2016 to 2022, as well as year-on-year growth rates, can be viewed in GlobalData’s micro revenue report. Buy the report here.
RareCyte is a provider of precision biology products and services for discovery, translational research, and clinical diagnostics. Its product portfolio includes CyteFinder imaging instrument, AccuCyte sample preparation system and Orion multiplex imaging instrument. Its Orion spatial biology platform enables same-day, 20-channel multiplexed tissue analysis. Its comprehensive liquid biopsy offerings enable characterization of CTC and other rare cells, as well as single cell retrieval for molecular analysis and CDx development. RareCyte is headquartered in Seattle, Washington, the US.
The key metrics of RareCyte related to marketed and pipeline products, ongoing clinical trials, active jobs and publications from 2022 are shown below:
As RareCyte is a privately held company, it is not required to disclose its financial information and there is no stock listed on an exchange. GlobalData has access to a proprietary data set containing invoice data from over 2,600 healthcare institutions in the US and is therefore able to use estimations of a company’s revenue and growth to value private companies such as RareCyte.
For a detailed understanding of the performance of RareCyte, buy the report here.